Open Access
Subscription Access
Determination, Development and Validation of Method for Simultaneous AXITINIB Pharmaceutical Dosage form by a Reverse Phase HPLC
Abstract
A simple and selective LC method is described for the determination of AXITINIB dosage forms. Chromatographic separation is observed on a c18 packing column using mobile phase with a mixture of TEA -Acetonitrile (50:50) with detected at 254nm. Linearity was observed in the range 15-45 µg /ml for AXITINIB (r2 =0.997) for drug estimated by the proposed methods was in good agreement with the label claim. The proposed method was validated. The accuracy of the methods was assessed by recovery studies at three different levels. The current study indicated the absence of interference of commonly encountered pharmaceutical additives. The method was precise to be indicated by the repeatability analysis, by showing %RSD > 2. All statistical data proved the validity of the methods and used for routine analysis of pharmaceutical dosage form.
References
"(Axitinib) Inlyt dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 25 January 2014.
Wilmes, LJ; Pallavicini, MG; Fleming, LM; Gibbs, J; Wang, D; Li, KL; Partridge, SC; Henry, RG; Shalinsky, DR; Hu-Lowe, D; Park, JW; McShane, TM; Lu, Y; Brasch, RC; Hylton, NM (April 2007). "AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging". Magnetic Resonance Imaging. 25 (3): 319–27. doi:10.1016/j.mri.2006.09.041. PMID 17371720.
Rini, B; Rixe, O; Bukowski, R; Michaelson, MD; Wilding, G; Hudes, G; Bolte, O; Steinfeldt, H; Reich, SD; Motzer, R (June 2005). "AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC)". Journal of Clinical Oncology ASCO Annual Meeting Proceedings. 23 (16S): 4509.
Rugo, HS; Herbst, RS; Liu, G; Park, JW; Kies, MS; Steinfeldt, HM; Pithavala, YK; Reich, SD; Freddo, JL; Wilding, G (August 2005). "Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results" (PDF). Journal of Clinical Oncology.
"FDA Approves Inlyta for Advanced Renal Cell Carcinoma". Drugs.com. January 27, 2012.
John Fauber; Elbert Chu (Oct 27, 2014). "The Slippery Slope: Is a Surrogate Endpoint Evidence of Efficacy?". Milwaukee Journal Sentinel/MedPage Today.
"INLYTA (axitinib) tablet, film coated [Pfizer Laboratories Div Pfizer Inc]". DailyMed. Pfizer Laboratories Div Pfizer Inc. September 2013. Retrieved 25 January 2014.
"Inlyta: EPAR - Product Information" (PDF). European Medicines Agency. Pfizer Ltd. 17 December 2013. Retrieved 25 January 2014.
"Inlyta 1 mg 3mg, 5 mg & 7mg film-coated tablets - Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Pfizer Limited. 5 December 2013. Retrieved 25 January 2014.
Jump up to: "PRODUCT INFORMATION INLYTA (axitinib)" (PDF). TGA eBusiness Services. Pfizer Australia Pty Ltd. 5 July 2013. Retrieved 25 January 2014.
Spano, JP; Chodkiewicz, C; Maurel, J; Wong, R; Wasan, H; Barone, C; Létourneau, R; Bajetta, E; Pithavala, Y; Bycott, P; Trask, P; Liau, K; Ricart, AD; Kim, S; Rixe, O (June 2008). "Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study". Lancet. "Pfizer pancreatic cancer drug fails, trial halted". Reuters. January 30, 2009.
"Pfizer's Phase III Trial in mRCC Turns Up Positive Results". 19 Nov 2010.
"ODAC Unanimously Supports Axitinib for Renal Cell Carcinoma". 7 Dec 2011. 14.ALK1/VEGF Combo Active in Advanced RCC. Jan 2017
Tea Pemovska; Johnson; Mika Kontro; Gretchen Repasky; Jeffrey Chen; Peter Wells; Ciarán Cronin; Michele McTigue; Olli Kallioniemi; Kimmo Porkka; Brion W. Murray; Krister Wennerberg. "Axitinib effectively inhibits BCR-ABL1(T315I) with a distinctbinding conformation". Nature. 519: "FDA Prescribing Information" (PDF). 30 Jan 2012.
Escudier, B; Gore, M. "Axitinib for the Management of Metastatic Renal Cell Carcinoma" (PDF). Drugs in R&d.
Refbacks
- There are currently no refbacks.